Regular long acting v short acting inhaled β2 agonists in adults and children with chronic asthma

Outcomes at 2–24 weeks (number of studies)Weighted mean difference (95% CI)
Morning peak expiratory flow (l/min) (n=8)33 (25 to 41)
Evening peak expiratory flow (l/min) (n=8)26 (18 to 33)
Forced expiratory volume in 1 second (l) (n=8)0.23 (0.14 to 0.31)
Daytime asthma symptom score (n=3)−0.15 (−0.23 to −0.06)
Night time asthma symptom score (n=3)−0.21 (−0.31 to −0.10)
Percentage of days without symptoms (n=2)10 (2 to 19)
Percentage of nights without symptoms (n=3)12 (8 to 16)
Daytime use of rescue bronchodilators (puffs/24 h) (n=4)−0.33 (−0.50 to −0.16)
Night time use of rescue bronchodilators (puffs/24 h) (n=4)−0.31 (−0.43 to −0.19)